mSmoICD . These chimeras were C-terminally tagged with Cherry, and were stably expressed in Smo-/-MEFs. Cells expressing rMAcChR mSmoICD were incubated overnight with acetylcholine (100 µM) or scopolamine (100 µM), while cells expressing mFz7 mSmoICD were incubated in DMEM. The cells were processed for immunofluorescence as in (a). Ciliary localization of the fusion protein was scored manually. MFz7 mSmoICD localizes to cilia constitutively, while rMAcChR mSmoICD localizes to cilia only upon treatment with agonist (acetylcholine) or antagonist (scopolamine). Scale bar = 2 µm. 
Supplementary note. Synthesis and characterization of sterol derivatives and BODIPY-SANT1
General methods for synthesis All solvents and reagents were obtained from commercial sources and were used without further purification. NMR spectra were recorded on a Varian 400 MHz NMR spectrometer or a Varian Oxford 600 MHz NMR spectrometer. NMR chemical shifts were expressed in ppm relative to internal solvent peaks, and coupling constants were measured in Hz. High-resolution mass spectra were obtained at the Harvard University Mass Spectrometry Facility, or were obtained in-house on a Bruker microTOF-QII instrument, using an ESI source. LC/MS was performed on a Waters Micromass ZQ instrument using an ESI source coupled to a Waters 2525 HPLC system operating in reverse mode with a Waters Sunfire TM C185 uM 4.6×50 mm column. Flash chromatography was performed on silica gel columns using a Biotage Isolera One flash purification system. Diastereomers of 20-OHC analogs were purified on a chiral RegisCell (25 cm×21.1 mm) column using a preparative HPLC system composed of a Waters 1525 binary pump and Waters 2467 UV absorbance detector.
Synthesis of 22-azacholesterol (22-NHC) derivatives (1-6)
General procedure for reductive amination of pregnenolone Following a reductive amination protocol 1 , pregnenolone (5-pregnen-3β-ol-20-one, 1.0 eq) and amine (1.0 eq) were mixed in 1,2-dichloroethane (c = 0.2 mol/L) and were then treated with sodium triacetoxyborohydride (1.5 eq) and AcOH (1.0 eq). The mixture was stirred at room temperature under nitrogen for 16 h. The reaction was quenched with 1M NaOH, and the product was extracted 3 times with diethyl ether. The ether layer was washed with brine and dried over Na 2 SO 4 . The solvent was evaporated to give the crude free base, which was purified by flash chromatography (silica gel, CH 2 Cl 2 /MeOH, gradient elution) to provide the 22-NHC analog as a mixture of diastereomers. The ratio between the diastereomers in the mixture was estimated by LC/MS. This mixture was further purified by flash chromatography (silica gel, CH 2 Cl 2 /CHCl 3 : MeOH:NH 4 OH(89:10:1), gradient elution) to yield the pure C20 diastereomers. 3S,8S,9S,10R,13S,14S,17S)-17-(1-((2-hydroxyethyl)amino)ethyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16 3S,8S,9S,10R,13S,14S,17S)-17-(1-((3-hydroxypropyl)amino)ethyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[α]phenanthren-3-ol (5) . Following the general procedure, compound 5 was obtained from pregnenolone (1.01 g, 3.2 mmol) and 3-amino-1- A solution of alkylmagnesium bromide or chloride (3.0 eq.) was added drop-wise over 10 min. The reaction mixture was stirred at 25 °C for 16 h and was then cooled to 0 °C. A saturated solution of NH 4 Cl was added and the mixture was stirred for 30 min, after which it was extracted 3 times with EtOAc. The organic phase was washed with brine and dried over anhydrous Na 2 SO 4 . Evaporation of the solvent gave a residue, which was purified by flash chromatography on silica gel (step-wise gradient elution, 0-70%
NaBH(OAc) 3 1,2-dichloroethane AcOH, 25 °C
6
EtOAc/hexane) to provide the 20-hydroxycholesterol analog as a mixture of diasteromers. This mixture was subjected to normal-phase chiral HPLC purification (6% i-PrOH/Hexane), to yield the pure diastereomers. (3S,10R,13S,17S)-17-(2-hydroxyhexan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol (20-OHC-Bu, 10) . Following the general procedure, compound 10 was obtained from pregnenolone (1.0 g) and butylmagnesium chloride (4.7 mL of a 2.0 M solution in THF) in dry THF (20 mL) as a white solid (415 mg, 35%). Further preparative chiral HPLC separation yielded the pure diastereomers (10a and 10b) as white solids. 1H), 1.43-1.84 (m, 12H), 1.15-1.43 (m, 15H), 1.03-1.15 (m, 4H), 0.94-1.03 (m, 2H), 0.85-0.94 (m, 4H), 0.84  (s, 3H), 0.80 (s, 3H) To a dry 250 mL flask equipped with a magnetic stir bar was added pregnenolone methyl ether (960 mg, 2.9 mmol, from Steraloids) and 5 mL anhydrous tetrahydrofuran. The solution was stirred under argon while 14.5 mL (29 mmol) of 2M pentyl magnesium bromide was added dropwise. The reaction was allowed to proceed overnight under argon. The reaction mix was diluted with 100 mL diethyl ether and quenched by the addition of 1% aqueous acetic acid. The organic phase was washed with water and brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product (TLC: 30% ethyl acetate/hexanes, starting material Rf = 0.33, product Rf = 0.38) was dissolved in a small amount of dichloromethane and purified by column chromatography using a gradient of 5-20% ethyl acetate in hexanes, yielding the product 13 as a colorless oil (806 mg, 69% (3S,10R,13S,17S)-17-(8-((tert-butyldimethylsilyl)oxy)-2-hydroxyoctan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[α]phenanthren-3-ol (14) . In a 2-necked round bottom flask equipped with a condenser, magnesium turnings (2.2 g, 89.1 mmol) were stirred in anhydrous THF (2 mL) under nitrogen. (6-Bromohexyloxy)-tert-butyldimethylsilane (5.3 g, 17.8 mmol) was dissolved in anhydrous THF (18 mL) and 1/10 of this solution was added to the flask, followed by a few drops of 1,2-dibromoethane. The mixture was warmed and stirred vigorously until cloudiness and bubbling was observed. The rest of the THF solution of (6-bromohexyloxy)-tert-butyldimethylsilane was slowly added to the flask to keep the reaction going. The reaction mixture was heated to reflux for an additional hour, and then cooled to room temperature. The Grignard reagent thus prepared was transferred drop-wise via syringe to a solution of pregnenolone (1.9 g, 5.9 mmol) in anhydrous THF (10 mL) at 0°C. The reaction was stirred at room temperature for 12 h under nitrogen and was quenched with aqueous NH 4 Cl, followed by extraction with EtOAc. The organic extract was washed with brine, dried over Na 2 SO 4 , and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (step-wise gradient elution, 0-30% EtOAc/Hexanes) to yield compound 14 (1.4 g, 46%) as a colorless, amorphous solid (mixture of diastereomers). 3S,10R,13S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16 ,17-tetradecahydro-1H-cyclopenta[α]phenanthren-17-yl)octane-1,7-diol (15). To compound 13 (1.1g, 2.1 mmol) in dry THF (15 mL) was added tetrabutylammonium fluoride (6.3 mL of a 1.0 M solution in THF, 6.3 mmol), and the reaction was stirred for 4 h. Upon reaction completion, water was added and most of the product was precipitated by addition of a large excess of Et 2 O. The organic phase was separated and the solvent was removed by rotary evaporation. The resulting residue was washed with water and CH 2 Cl 2 , and was combined with the solid obtained by ether precipitation. The combined solids were dried in vacuo to yield the crude 15 (0.72 g, 82 %) as a white solid (mixture of diastereomers).
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1 H NMR (600 MHz 3S,10R,13S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15 (47.2 mg, 0.17 mmol) in THF (15 mL) and 15 mL of an aqueous solution of NaHCO 3 (0.5 M) and K 2 CO 3 (0.05 M) were vigorously stirred at room temperature. N-chlorosuccinimide (340.5 mg, 2.6 mmol) was then added, and stirring was maintained for 16 h. The organic phase was separated, and the aqueous phase was diluted with brine and extracted 3 times with CH 2 Cl 2 (some precipitate might form and just filter to collect the solid and filtrate). The combined organic phases were concentrated in vacuo, the residue was dissolved in a small amount of CH 2 Cl 2 /MeOH and was purified by flash chromatography on silica gel (step-wise gradient elution, 0-40% EtOAc/hexanes) to yield the aldehyde 16 (443 mg, 54%) as a white solid (mixture of diastereomers). 3S,10R,13S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16 ,17-tetradecahydro-1H-cyclopenta[α]phenanthren-17-yl)-4,7,10-trioxa-14-azadocosan-21-ol (20-OHC-PEG-NH 2 , 17). Compound 15 (208 mg, 0.5 mmol) and 4,7,10-trioxa-1,13-tridecanediamine (220 mg, 1 mmol) were mixed in 1,2-dichloroethane (5 mL) and then treated with sodium triacetoxyborohydride (159 mg, 0.75 mmol). The mixture was stirred at room temperature for 16 h until the reactants were consumed, as determined by TLC. The reaction mix was concentrated in vacuo, the residue was dissolved in DMSO and was purified by preparative reverse-phase HPLC on a Waters Symmetry C18 column (19 x 50 mm, 5µM). Elution was with a gradient of 15-80% MeOH in water with 0.035% trifluoroacetic acid, over 15 min and at a flow rate of 20 mL/min. The product 17 (mixture of diastereomers) was obtained as the di(trifluoroacetate) salt (yellow oil, 154 mg, 36%). 
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Synthesis of BODIPY-SANT1 (17-21)
tert-butyl 4-iodobenzylcarbamate (18). 4-Iodobenzylamine (349.6 mg, 1.5 mmol) and triethylamine (0.44 mL, 3.15 mmol) were dissolved in dichloromethane (6 mL), and Boc anhydride (343.7 mg, 1.6 mmol) in dichloromethane (6 mL) was added drop-wise. After stirring for 16 h at room temperature, the reaction mixture was washed with 1N HCl, saturated aqueous NaHCO3, and brine, then dried over anhydrous Na 2 SO 4 and concentrated to yield compound 18 as a white solid (499 mg, 100 %). 45 (s, 9H) . Characterization matched the data reported for compound 18 6 .
18:
tert-butyl 4-(4-formyl-3,5-dimethyl-1H-pyrazol-1-yl)benzylcarbamate (19).
Compound 19 was obtained by N-arylation following a reported protocol 7 . To a screw cap glass vial were added CuI (4.6 mg, 0.024 mmol, 5 mol%), 3,5-dimethyl-1H-pyrazole-4-carbaldehyde (59.5 mg, 0.48 mmol), K 2 CO 3 (139.3 mg, 1.0 mmol), and a stir bar. The reaction vessel was fitted with a rubber septum, was evacuated and back-filled with argon, and this sequence was repeated twice. Aryl iodide 18 (191.8 mg, 0.58 mmol), (1S,2S)-N 1 ,N 2 -dimethylcyclohexane-1,2-diamine (13.6 mg, 0.96 mmol, 20 mol%) and toluene (2 mL) were then added successively under a stream of argon. The reaction vial was sealed and immersed in an oil bath preheated to 110 °C, and the reaction was stirred for 24 h. The reaction mixture was cooled to room temperature, diluted with EtOAc and filtered through Celite. The filtrate was washed with aqueous NH 4 OH (v/v, 1/1) and brine, then was dried over Na 2 SO 4 and concentrated in vacuo. The resulting residue was purified by flash chromatography on silica gel (step-wise gradient from 9:1 to 2:3 hexane/EtOAc) to provide compound 19 as a yellow oil (17.0 mg, 11 %).
19:
1 H NMR (600 MHz, CDCl reflux for 12 h. After concentration, the resulting residue was purified by flash chromatography on silica gel (step-wise gradient elution from 100:1 to 9:1 CH 2 Cl 2 /MeOH) to provide compound 20 as a yellow oil (22.5 mg, 100 %). The reaction mixture was stirred at room temperature for 18 h and then evaporated to dryness under a stream of nitrogen gas. Purification by flash chromatography on silica gel (step-wise gradient from 100:1 to 85:15 CH 2 Cl 2 /MeOH) yielded the fluorescent amide 22 as a dark red solid (7.8 mg, 89 %).
20:
22:
1 H NMR (400 MHz, 
